{"id":"W3043725666","doi":"10.1136/esmoopen-2020-000672","title":"Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study","year":2020,"lang":"en","type":"article","venue":"ESMO Open","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis Pharma; Novartis Pharmaceuticals Corporation","keywords":"Carboplatin; Medicine; Open label; Lomustine; Internal medicine; Oncology; Glioblastoma; Phases of clinical research; Randomized controlled trial; Clinical trial; Chemotherapy; Cisplatin; Vincristine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002455646,0.0003821034,0.001026114,0.0001066387,0.0001467438,0.0001790319,0.0005460031,0.00006295917,0.0007091446],"category_scores_gemma":[0.0003522785,0.0002228158,0.0000388016,0.0006552935,0.00003610368,0.0002851037,0.0008499231,0.0002383888,0.00006420688],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002112717,"about_ca_system_score_gemma":0.0002594674,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001442496,"about_ca_topic_score_gemma":0.002548974,"domain_scores_codex":[0.9976257,0.000157398,0.0006014018,0.0007337225,0.0004689755,0.0004127941],"domain_scores_gemma":[0.9985669,0.0001422653,0.0002265244,0.0004702905,0.0001534922,0.0004405449],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5419088,0.09043612,0.319052,0.0001128727,0.001119199,0.003715967,0.01032219,0.00007778822,0.00003930077,0.000008752011,0.009696696,0.02351032],"study_design_scores_gemma":[0.855256,0.03352359,0.1050379,0.0004042494,0.0005936119,0.000006067473,0.0008652296,0.001616853,0.0004243146,0.000001100698,0.00188876,0.0003822821],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9826888,0.00005709499,0.000002449547,0.001343217,0.0001050677,0.01499649,0.00005442125,0.00003822392,0.0007142342],"genre_scores_gemma":[0.9972672,0.00001016962,0.0006449468,0.0005866447,0.00005458988,0.001077626,0.0001329024,0.00005300373,0.000172871],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3133473,"threshold_uncertainty_score":0.9086165,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05163462450066753,"score_gpt":0.3471709034432321,"score_spread":0.2955362789425646,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}